Obesity and CHD
This article was originally published in The Tan Sheet
Executive Summary
Even without additional risk factors, obesity in young adulthood and middle-age carries an increased risk of hospitalization or death from coronary heart disease, cardiovascular disease or diabetes in older age compared to normal weight individuals, a study in the Jan. 11 Journal of the American Medical Association finds. For instance, the risk of death from CHD was 43% higher for obese individuals in the low-risk group compared to normal weight individuals at the same risk level, according to Lijing Yan, PhD, Feinberg School of Medicine, Northwestern University, et al. The findings, which were gleaned from a multivariable analysis of 17,643 participants in the Chicago Heart Association Detection Project, have "significant public health implications," the authors conclude. GlaxoSmithKline's switch application for the anti-obesity drug Xenical (orlistat) will be reviewed by two FDA advisory committees Jan. 23 (1"The Tan Sheet" Jan. 2, 2006, p. 3)...
You may also be interested in...
Xenical Short-Term Switch Odds Slimmer Than Long-Term – Experts
Xenical's long-term prospect for switch appears promising, but its chances of being recommended for OTC sale by an upcoming advisory panel are slim, some switch experts say
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.